<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909424</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00370-41</org_study_id>
    <nct_id>NCT04909424</nct_id>
  </id_info>
  <brief_title>Prevalence of Cutaneous Enterococci at Femoral Insertion Site in Transcatheter Aortic Valve Implantation (TAVI)</brief_title>
  <acronym>Entero-TAVI</acronym>
  <official_title>Prevalence of Cutaneous Enterococci at Femoral Insertion Site in Transcatheter Aortic Valve Implantation (TAVI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general rules of antibiotic prophylaxis in surgery or interventional medicine include the&#xD;
      choice of an antibiotic active on the bacteria most frequently encountered in surgical site&#xD;
      infections. This antibiotic must cover, the bacteria present on the skin and recognized as&#xD;
      responsible for surgical site infections.&#xD;
&#xD;
      The aim of this study is to identify bacteria found in skin flora in the inguinal region of&#xD;
      patients undergoing Transcatheter Aortic Valve Implantation (TAVI). Flora found will allow to&#xD;
      evaluate the impact of skin preparation and antibiotic prophylaxis protocols as they are&#xD;
      currently practiced.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Enterococci prevalence</measure>
    <time_frame>At Day 0 at TAVI intervention time (preoperative)</time_frame>
    <description>Proportion of patients with Enterococcus feacalis and other Enterococci in inguinal flora before TAVI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin flora of the groin</measure>
    <time_frame>At Day 0 at TAVI intervention time (preoperative) before skin disinfection</time_frame>
    <description>Bacteria profile of inguinal skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin flora of the groin</measure>
    <time_frame>At Day 0 at TAVI intervention time (preoperative) after skin disinfection</time_frame>
    <description>Bacteria profile of inguinal skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious events</measure>
    <time_frame>From day of TAVI to 1 year after intervention</time_frame>
    <description>Occurrence of infective endocarditis or other infectious adverse events</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Valve Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        In hospital patients for pre TAVI assessment at Clinique Pasteur&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient scheduled for aortic valve replacement by TAVI procedure with trans femoral&#xD;
             approach&#xD;
&#xD;
          -  Patient with pre-TAVI assessment performed at Clinique Pasteur&#xD;
&#xD;
          -  Patient affiliated or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient accepting to participate and having given his no objection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TAVI procedure by non-trans femoral approach&#xD;
&#xD;
          -  Protected patients: Adults under guardianship or other legal protection; Pregnant or&#xD;
             breastfeeding woman; Hospitalized without consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bonnet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Combes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit Fontenel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit FONTENEL, MD</last_name>
    <phone>+33 5 62 21 16 00</phone>
    <email>bfontenel@clinique-pasteur.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Fontenel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoit Fontenel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Combes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Honton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jerome Van Rothem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>RaphaÃ«l Philippart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine Sauguet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit Monteil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Issam Abouliatim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Berthoumieu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Bonnet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>Dr Benoit Fontenel</investigator_full_name>
    <investigator_title>Principal investigator, MD</investigator_title>
  </responsible_party>
  <keyword>Enterococci</keyword>
  <keyword>Infective endocarditis</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <keyword>TAVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

